Halozyme Therapeutics (HALO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Drug Deliverysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 13.04% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Is Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?
- Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
- 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
- Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
- Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?
- Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
- Sector Update: Healthcare Stocks Rise in Afternoon Trading
- Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Halozyme Therapeutics.
Full HALO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.